EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische StudieOpen Access

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors

Saket Girotra iD, Amanda Stebbins iD, Lisa Wruck iD, Guillaume Marquis-Gravel iD, Kamal Gupta iD, Peter Farrehi iD, Catherine P Benziger iD, Mark B Effron iD, Jeffrey Whittle iD, Daniel Muñoz iD, Sunil Kripalani iD, R David Anderson iD und 8 weitere

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.123.030385 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Saket Girotra und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center Dallas TX. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Acute Coronary Syndrome, Atherosclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The ADAPTABLE (Aspirin Dosing: A Patient‐Centric Trial Assessing Benefits and Long‐Term Effectiveness) was a large, pragmatic, randomized controlled trial that found no difference between high‐ versus low‐dose aspirin for secondary prevention of atherosclerotic cardiovascular disease. Whether concomitant P2Y12 inhibitor therapy modifies the effect of aspirin dose on clinical events remains unclear. Methods and Results Participants in ADAPTABLE were stratified according to baseline use of clopidogrel or prasugrel (P2Y12 group). The primary effectiveness end point was a composite of death, myocardial infarction, or stroke; and the primary safety end point was major bleeding requiring blood transfusions. We used multivariable Cox regression to compare the relative effectiveness and safety of aspirin dose within P2Y12 and non‐P2Y12 groups. Of 13 815 (91.6%) participants with available data, 3051 (22.1%) were receiving clopidogrel (2849 [93.4%]) or prasugrel (203 [6.7%]) at baseline. P2Y12 inhibitor use was associated with higher risk of the primary effectiveness end point (10.86% versus 6.31%; adjusted hazard ratio [HR], 1.40 [95% CI, 1.22–1.62]) but was not associated with bleeding (0.95% versus 0.53%; adjusted HR, 1.42 [95% CI, 0.91–2.22]). We found no interaction in the relative effectiveness and safety of high‐ versus low‐dose aspirin by P2Y12 inhibitor use. Overall, dose switching or discontinuation was more common in the high‐dose compared with low‐dose aspirin group, but the pattern was not modified by P2Y12 inhibitor use.

Conclusions

In this prespecified analysis of ADAPTABLE, we found that the relative effectiveness and safety of high‐ versus low‐dose aspirin was not modified by baseline P2Y12 inhibitor use. Registration https://www.clinical.trials.gov . Unique identifier: NCT02697916.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesAcute Coronary SyndromeAtherosclerosisHumansClopidogrelPlatelet Aggregation InhibitorsPrasugrel HydrochlorideTiclopidineSecondary PreventionPurinergic P2Y Receptor AntagonistsAspirinHemorrhage

Stichwörter der Autor:innen

aspirinatherosclerotic cardiovascular diseasesecondary prevention

Substanzen

ClopidogrelPlatelet Aggregation InhibitorsPrasugrel HydrochlorideTiclopidinePurinergic P2Y Receptor AntagonistsAspirin

Autor:innen und Institutionen

  • University of Texas Southwestern Medical Center Dallas TX.
  • Duke University Medical Center and Duke Clinical Research Institute Durham NC.
  • Université de Montréal Montreal QC Canada.
  • University of Kansas Medical Center Kansas City KS.
  • University of Michigan Ann Arbor MI.
  • Essentia Health Heart and Vascular Center Duluth MN.

ORCID-Profile: Saket Girotra, Amanda Stebbins, Lisa Wruck, Guillaume Marquis-Gravel, Kamal Gupta, Peter Farrehi, Catherine P Benziger, Mark B Effron, Jeffrey Whittle, Daniel Muñoz, Sunil Kripalani, R David Anderson, Sandeep K Jain, Tamar S Polonsky, Faraz S Ahmad, Russell L Rothman, Robert A Harrington, Adrian F Hernandez, W Schuyler Jones

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Girotra, S., Stebbins, A., Wruck, L., Marquis-Gravel, G., Gupta, K., Farrehi, P., Benziger, C. P., Effron, M. B., Whittle, J., Muñoz, D., Kripalani, S., Anderson, R. D., Jain, S. K., Polonsky, T. S., Ahmad, F. S., Roe, M. T., Rothman, R. L., Harrington, R. A., Hernandez, A. F., & Jones, W. S. (2023). Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.030385

Vancouver

Girotra S, Stebbins A, Wruck L, Marquis-Gravel G, Gupta K, Farrehi P, et al. Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. Journal of the American Heart Association. 2023. doi:10.1161/jaha.123.030385

BibTeX
@article{Girotra2023,
  author = {Girotra, Saket and Stebbins, Amanda and Wruck, Lisa and Marquis-Gravel, Guillaume and Gupta, Kamal and Farrehi, Peter and Benziger, Catherine P and Effron, Mark B and Whittle, Jeffrey and Muñoz, Daniel and Kripalani, Sunil and Anderson, R David and Jain, Sandeep K and Polonsky, Tamar S and Ahmad, Faraz S and Roe, Matthew T and Rothman, Russell L and Harrington, Robert A and Hernandez, Adrian F and Jones, W Schuyler},
  title = {Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.123.030385}
}
Kostenlos starten →